PubRank

Marcus Groettrup

Author PubWeight™ 74.89‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 2009 2.62
2 Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 2002 2.61
3 Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell 2012 1.83
4 Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins. Cell 2013 1.74
5 FAT10, a ubiquitin-independent signal for proteasomal degradation. Mol Cell Biol 2005 1.53
6 The immunoproteasome in antigen processing and other immunological functions. Curr Opin Immunol 2012 1.52
7 CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood 2003 1.46
8 Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J Immunol 2006 1.40
9 Analysis and expression of a cloned pre-T cell receptor gene. Science. 1994. 266: 1208-1212. J Immunol 2009 1.39
10 Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J Immunol 2010 1.36
11 Substantial reduction of naïve and regulatory T cells following traumatic stress. Brain Behav Immun 2009 1.33
12 NEDD8 ultimate buster-1L interacts with the ubiquitin-like protein FAT10 and accelerates its degradation. J Biol Chem 2004 1.28
13 TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 2008 1.26
14 Opposite fate of endocytosed CCR7 and its ligands: recycling versus degradation. J Immunol 2006 1.25
15 An altered T cell repertoire in MECL-1-deficient mice. J Immunol 2006 1.25
16 UBE1L2, a novel E1 enzyme specific for ubiquitin. J Biol Chem 2007 1.25
17 Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus. J Immunol 2004 1.21
18 Long-lived signal peptide of lymphocytic choriomeningitis virus glycoprotein pGP-C. J Biol Chem 2003 1.18
19 PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev 2005 1.15
20 Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine 2003 1.14
21 The ubiquitin-like modifier FAT10 interacts with HDAC6 and localizes to aggresomes under proteasome inhibition. J Cell Sci 2008 1.13
22 Posttraumatic stress disorder is associated with an enhanced spontaneous production of pro-inflammatory cytokines by peripheral blood mononuclear cells. BMC Psychiatry 2013 1.09
23 Cross-presentation of the long-lived lymphocytic choriomeningitis virus nucleoprotein does not require neosynthesis and is enhanced via heat shock proteins. J Immunol 2005 1.06
24 Encapsulation of proteins and peptides into biodegradable poly(D,L-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells. Vaccine 2005 1.05
25 Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother 2006 1.04
26 Prostaglandin E(2) enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells. Blood 2008 1.04
27 Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO. J Leukoc Biol 2007 1.01
28 Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation. J Immunol 2012 1.01
29 A cytomegalovirus inhibitor of gamma interferon signaling controls immunoproteasome induction. J Virol 2004 0.99
30 Degradation of FAT10 by the 26S proteasome is independent of ubiquitylation but relies on NUB1L. FEBS Lett 2009 0.97
31 Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response. J Drug Target 2009 0.97
32 USE1 is a bispecific conjugating enzyme for ubiquitin and FAT10, which FAT10ylates itself in cis. Nat Commun 2010 0.96
33 Reduced immunoproteasome formation and accumulation of immunoproteasomal precursors in the brains of lymphocytic choriomeningitis virus-infected mice. J Immunol 2010 0.96
34 Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis. EMBO Mol Med 2014 0.95
35 The UBA domains of NUB1L are required for binding but not for accelerated degradation of the ubiquitin-like modifier FAT10. J Biol Chem 2006 0.95
36 The combination of TLR-9 adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA. Int J Cancer 2010 0.94
37 The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol 2009 0.93
38 Immunoproteasomes are essential for survival and expansion of T cells in virus-infected mice. Eur J Immunol 2010 0.92
39 Distinct motifs in the chemokine receptor CCR7 regulate signal transduction, receptor trafficking and chemotaxis. J Cell Sci 2008 0.92
40 The proteomic analysis of endogenous FAT10 substrates identifies p62/SQSTM1 as a substrate of FAT10ylation. J Cell Sci 2012 0.92
41 Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice. J Control Release 2012 0.92
42 No essential role for tripeptidyl peptidase II for the processing of LCMV-derived T cell epitopes. Eur J Immunol 2007 0.91
43 Delivery of tumor antigens to dendritic cells using biodegradable microspheres. Methods Mol Med 2005 0.89
44 CD8- dendritic cells and macrophages cross-present poly(D,L-lactate-co-glycolate) acid microsphere-encapsulated antigen in vivo. J Immunol 2011 0.89
45 Why the structure but not the activity of the immunoproteasome subunit low molecular mass polypeptide 2 rescues antigen presentation. J Immunol 2012 0.89
46 Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy. J Immunol Methods 2004 0.88
47 FAT10 and NUB1L bind to the VWA domain of Rpn10 and Rpn1 to enable proteasome-mediated proteolysis. Nat Commun 2012 0.88
48 Ubiquitylation of the chemokine receptor CCR7 enables efficient receptor recycling and cell migration. J Cell Sci 2012 0.87
49 Cross-talk between TCR and CCR7 signaling sets a temporal threshold for enhanced T lymphocyte migration. J Immunol 2011 0.86
50 NUB1 modulation of GSK3β reduces tau aggregation. Hum Mol Genet 2012 0.86
51 FAT10 : Activated by UBA6 and Functioning in Protein Degradation. Subcell Biochem 2010 0.86
52 The antiviral immune response in mice devoid of immunoproteasome activity. J Immunol 2011 0.85
53 Prostaglandin E2 inhibits IL-23 and IL-12 production by human monocytes through down-regulation of their common p40 subunit. Mol Immunol 2012 0.85
54 The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles. Biomaterials 2006 0.85
55 A novel cytosolic class I antigen-processing pathway for endoplasmic-reticulum-targeted proteins. EMBO Rep 2007 0.85
56 FAT10ylation as a signal for proteasomal degradation. Biochim Biophys Acta 2013 0.84
57 Attenuation of the cytotoxic T lymphocyte response to lymphocytic choriomeningitis virus in mice subjected to chronic social stress. Brain Behav Immun 2010 0.81
58 Stable antigen is most effective for eliciting CD8+ T-cell responses after DNA vaccination and infection with recombinant vaccinia virus in vivo. J Virol 2012 0.81
59 An artificial PAP gene breaks self-tolerance and promotes tumor regression in the TRAMP model for prostate carcinoma. Mol Ther 2011 0.80
60 Quantitative analysis of gene expression relative to 18S rRNA in carcinoma samples using the LightCycler instrument and a SYBR GreenI-based assay: determining FAT10 mRNA levels in hepatocellular carcinoma. Methods Mol Biol 2008 0.80
61 Detection and analysis of FAT10 modification. Methods Mol Biol 2012 0.79
62 Tumor eradication by immunotherapy with biodegradable PLGA microspheres--an alternative to incomplete Freund's adjuvant. Int J Cancer 2011 0.79
63 Microencapsulation of inorganic nanocrystals into PLGA microsphere vaccines enables their intracellular localization in dendritic cells by electron and fluorescence microscopy. J Control Release 2011 0.79
64 Advances in prostate cancer immunotherapies. Drugs Aging 2007 0.78
65 The inherited blindness protein AIPL1 regulates the ubiquitin-like FAT10 pathway. PLoS One 2012 0.78
66 Immunoproteasome-specific inhibitors and their application. Methods Mol Biol 2012 0.77
67 Investigations into the auto-FAT10ylation of the bispecific E2 conjugating enzyme UBA6-specific E2 enzyme 1. FEBS J 2014 0.77
68 Endosomal trafficking of open Major Histocompatibility Class I conformers--implications for presentation of endocytosed antigens. Mol Immunol 2012 0.77
69 Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T-cell stimulation. Prostate 2005 0.76
70 No evidence for immunoproteasomes in chicken lymphoid organs and activated lymphocytes. Immunogenetics 2014 0.76
71 Using protease inhibitors in antigen presentation assays. Methods Mol Biol 2013 0.76
72 The non-peptidic HIV protease inhibitor tipranavir and two synthetic peptidomimetics (TS98 and TS102) modulate Pneumocystis carinii growth and proteasome activity of HEL299 cell line. J Eukaryot Microbiol 2006 0.76
73 Identification of the molecular composition of the 20S proteasome of mouse intestine by high-resolution mass spectrometric proteome analysis. Methods Mol Biol 2009 0.75
74 Editorial overview: Molecular immunology: targeting the immune system. Curr Opin Chem Biol 2014 0.75
75 Identification of homozygous transgenic mice by genomic real-time PCR. Methods Mol Biol 2008 0.75